ClinicalTrials.gg
CompletedNCT02200614ARAMISUpdated Jun 28, 2022Results posted

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

A Phase 3 interventional study of Darolutamide (Nubeqa, BAY1841788) and Placebo in Prostate Cancer Non-Metastatic and Castration-Resistant, sponsored by Bayer. Completed at 404 sites in 36 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,509
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
Largest of 59
1,509 · median 80
Started
2014
the only one that year
Phase 3
12 of 59
5 open now
Registered
4th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one has the largest enrollment, is the only one that started in 2014, is one of 12 in phase 3, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

03

Conditions studied

  • Prostate Cancer Non-Metastatic
  • Castration-Resistant

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
  • Castration-resistant prostate cancer (CRPC) with castrate level of serum testosterone.
  • Prostate-specific Antigen (PSA) doubling time of ≤ 10 months and PSA > 2ng/ml.
  • (ECOG) performance status of 0-1.
  • Blood counts at screening: ≥ 9.0 g/dl, ≥ 1500/µl, count ≥ 100,000/µl.
  • Screening values of serum (ALT) and/or aspartate transaminase (AST) ≤ 2.5 x (ULN), total ≤ 1.5 x ULN, creatinine ≤ 2.0 x ULN.
  • Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of disease at any time or presence of detectable metastases.
  • Acute toxicities of prior treatments and procedures not resolved to grade ≤ 1 or baseline before randomisation.
  • Prior treatment with: second generation androgen receptor (AR) inhibitors, other AR inhibitors, or CYP17 enzyme inhibitor.
  • Use of estrogens or 5-α reductase inhibitors or AR inhibitors.
  • Prior chemotherapy or immunotherapy for prostate cancer.
  • Use of systemic .
  • Radiation therapy within 12 weeks before randomisation.
  • Severe or uncontrolled concurrent disease, infection or co-morbidity.
  • Treatment with bisphosphonate or denosumab within 12 weeks before randomisation.
  • Known to the study treatment or any of its ingredients.
  • Major surgery within 28 days before randomisation.
  • Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure (NYHA) Class III or IV.
  • Uncontrolled hypertension.
  • Prior .
  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
  • Active viral hepatitis, active (HIV) or chronic liver disease.
  • Treatment with any investigational drug within 28 days before randomisation.
  • Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,509 participants (actual)

Study arms

  • Experimental
    Darolutamide (BAY1841788)

    Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.

    Drug: Darolutamide (Nubeqa, BAY1841788)

  • Placebo comparator
    Placebo

    Participants received matching placebo 2 tablets twice daily with food.

    Drug: Placebo

Interventions

  • Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.

    Also known as: ODM-201

  • DrugPlacebo

    Matching placebo 2 tablets twice daily with food.

06

What researchers measure

Primary outcomes

  1. Metastasis-Free Survival

    Metastasis-Free Survival (MFS) is defined as the time from randomisation to evidence of metastasis or death from any cause, whichever occurs first (cut-off date 15 Nov 2019)

    Time frame: From randomization to the time approximately 385 MFS events were observed (approximately 48 months)

Secondary outcomes

  1. Overall Survival - Primary Analysis

    Overall Survival (OS) was defined as the time from randomization to death due to any cause.

    Time frame: From randomization of the first subject to the time approximatively 140 death events were observed (approximately 48 months)

  2. Time to Pain Progression - Primary Analysis

    Time to pain progression (PP) is defined as time from randomization to pain progression, where progression is defined as an increase of 2 or more points from baseline in question 3 of the Brief Pain Inventory-Short Form questionnaire (BPI-SF) related to the worst pain in the last 24 hours taken as a 7-day average for post-baseline scores, or initiation of short or long-acting opioids for pain, whichever comes first. Initiation or change in the use of other non-opioid analgesics is not used in the analysis of pain progression.

    Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)

  3. Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary Analysis

    The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle.

    Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)

  4. Time to First Symptomatic Skeletal Event (SSE) - Primary Analysis

    The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE.

    Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)

  5. Overall Survival - Final Analysis

    Overall Survival (OS) was defined as the time from randomization to death due to any cause. The final analysis was done at the time of the data cut-off (15 NOV 2019).

    Time frame: From randomization of the first subject to the time approximatively 254 death events were observed (approximately 56 months)

  6. Time to Pain Progression - Final Analysis

    For time to pain progression, the analysis performed using the primary completion cut-off data (03 SEP 2018) was considered final and no new analysis was performed for time to pain progression.

    Time frame: From randomization until last study treatment (assessed every 4 months) (approximately 48 months)

  7. Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final Analysis

    The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle. The final analysis was done at the time of the data cut-off (15 NOV 2019).

    Time frame: From randomization until initiation of first cytotoxic chemotherapy treatment (approximately 59 months)

  8. Time to First Symptomatic Skeletal Event (SSE) - Final Analysis

    The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE. The final analysis was done at the time of the data cut-off (15 NOV 2019).

    Time frame: From randomization until occurrence of first SSE event (approximately 59 months)

07

Results

Posted Oct 29, 2019

Participant flow

Study was conducted at multiple centers in 36 countries between 12 September 2014 (first participant first visit) and 14 June 2021 (last participant last visit).

Double Blind Treatment
Participant flow — Double Blind Treatment
MilestoneDarolutamide (BAY1841788)Placebo
Started955554
Completed591170
Not completed364384
Withdrew: Adverse event8648
Withdrew: Confirmed metastasis120140
Withdrew: Judgment of the investigator5999
Withdrew: Metastasis by local reading13
Withdrew: Other reason62
Withdrew: Personal reason7785
Withdrew: Protocol deviation147
Withdrew: Not treated10
Open Label
Participant flow — Open Label
MilestoneDarolutamide (BAY1841788)Placebo
Started591170
Completed295114
Not completed29656
Withdrew: Adverse event4111
Withdrew: Confirmed metastasis10
Withdrew: Judgment of the investigator292
Withdrew: Metastasis by local reading13827
Withdrew: Other reason224
Withdrew: Personal reason608
Withdrew: Protocol deviation32
Withdrew: Missing22

Outcome measures

PrimaryMetastasis-Free Survival

Metastasis-Free Survival (MFS) is defined as the time from randomisation to evidence of metastasis or death from any cause, whichever occurs first (cut-off date 15 Nov 2019)

Time frame:
From randomization to the time approximately 385 MFS events were observed (approximately 48 months)
Reported as:
Median · months
Metastasis-Free Survival
monthsDarolutamide (BAY1841788)Placebo
Metastasis-Free Survival40.37 (34.33 to NA)18.43 (15.51 to 22.34)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = <0.000001 · Hazard ratio (hr): 0.413 · 95% CI 0.341 to 0.500Hazard ratio and 95% Confidence Interval (CI) was based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryOverall Survival - Primary Analysis

Overall Survival (OS) was defined as the time from randomization to death due to any cause.

Time frame:
From randomization of the first subject to the time approximatively 140 death events were observed (approximately 48 months)
Reported as:
Median · months
Overall Survival - Primary Analysis
monthsDarolutamide (BAY1841788)Placebo
Overall Survival - Primary AnalysisNA (44.45 to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.045210 · Hazard ratio (hr): 0.706 · 95% CI 0.501 to 0.994The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryTime to Pain Progression - Primary Analysis

Time to pain progression (PP) is defined as time from randomization to pain progression, where progression is defined as an increase of 2 or more points from baseline in question 3 of the Brief Pain Inventory-Short Form questionnaire (BPI-SF) related to the worst pain in the last 24 hours taken as a 7-day average for post-baseline scores, or initiation of short or long-acting opioids for pain, whichever comes first. Initiation or change in the use of other non-opioid analgesics is not used in the analysis of pain progression.

Time frame:
From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Reported as:
Median · months
Time to Pain Progression - Primary Analysis
monthsDarolutamide (BAY1841788)Placebo
Time to Pain Progression - Primary Analysis40.31 (33.21 to 41.20)25.36 (19.09 to 29.63)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.000008 · Hazard ratio (hr): 0.647 · 95% CI 0.533 to 0.785The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryTime to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary Analysis

The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle.

Time frame:
From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Reported as:
Median · months
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary Analysis
monthsDarolutamide (BAY1841788)Placebo
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary AnalysisNA (NA to NA)38.21 (35.55 to 41.89)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = <0.000001 · Hazard ratio (hr): 0.433 · 95% CI 0.314 to 0.595The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryTime to First Symptomatic Skeletal Event (SSE) - Primary Analysis

The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE.

Time frame:
From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Reported as:
Median · months
Time to First Symptomatic Skeletal Event (SSE) - Primary Analysis
monthsDarolutamide (BAY1841788)Placebo
Time to First Symptomatic Skeletal Event (SSE) - Primary AnalysisNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.011262 · Hazard ratio (hr): 0.428 · 95% CI 0.218 to 0.842The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryOverall Survival - Final Analysis

Overall Survival (OS) was defined as the time from randomization to death due to any cause. The final analysis was done at the time of the data cut-off (15 NOV 2019).

Time frame:
From randomization of the first subject to the time approximatively 254 death events were observed (approximately 56 months)
Reported as:
Median · months
Overall Survival - Final Analysis
monthsDarolutamide (BAY1841788)Placebo
Overall Survival - Final AnalysisNA (56.14 to NA)NA (46.91 to NA)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.003048 · Hazard ratio (hr): 0.685 · 95% CI 0.533 to 0.881The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryTime to Pain Progression - Final Analysis

For time to pain progression, the analysis performed using the primary completion cut-off data (03 SEP 2018) was considered final and no new analysis was performed for time to pain progression.

Time frame:
From randomization until last study treatment (assessed every 4 months) (approximately 48 months)
Reported as:
Median · months
Time to Pain Progression - Final Analysis
monthsDarolutamide (BAY1841788)Placebo
Time to Pain Progression - Final Analysis40.31 (33.21 to 41.20)25.36 (19.09 to 29.63)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.000008 · Hazard ratio (hr): 0.647 · 95% CI 0.533 to 0.785The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryTime to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final Analysis

The time to cytotoxic chemotherapy was defined as the time from randomization to the start of the first cytotoxic chemotherapy cycle. The final analysis was done at the time of the data cut-off (15 NOV 2019).

Time frame:
From randomization until initiation of first cytotoxic chemotherapy treatment (approximately 59 months)
Reported as:
Median · months
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final Analysis
monthsDarolutamide (BAY1841788)Placebo
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final AnalysisNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.000044 · Hazard ratio (hr): 0.579 · 95% CI 0.444 to 0.755The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).
SecondaryTime to First Symptomatic Skeletal Event (SSE) - Final Analysis

The time to the first SSE was defined as the time from randomization to the occurrence of the first SSE. The final analysis was done at the time of the data cut-off (15 NOV 2019).

Time frame:
From randomization until occurrence of first SSE event (approximately 59 months)
Reported as:
Median · months
Time to First Symptomatic Skeletal Event (SSE) - Final Analysis
monthsDarolutamide (BAY1841788)Placebo
Time to First Symptomatic Skeletal Event (SSE) - Final AnalysisNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide (BAY1841788) vs Placebo · Log Rank · p = 0.005294 · Hazard ratio (hr): 0.484 · 95% CI 0.287 to 0.815The hazard ratio and its 95% CI were based on Cox Regression Model, stratified by Prostate-specific antigen doubling time (PSADT) (≤ 6 months vs. \> 6 months) and use of osteoclast-targeted therapy (No, Yes).

Adverse events

Collected over From start of study drug administration until 30 days after last treatment (last cut-off date 14 JUN 2021). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Darolutamide (DB)155/954 (16.2%)251/954 (26.3%)673/954 (70.5%)
Darolutamide (DB+OL)224/954 (23.5%)367/954 (38.5%)742/954 (77.8%)
Placebo (DB)137/554 (24.7%)121/554 (21.8%)354/554 (63.9%)
Placebo+Darolutamide (CO)16/170 (9.4%)43/170 (25.3%)110/170 (64.7%)
Most frequent serious events
Showing 10 of 375
Most frequent serious events
EventDarolutamide (DB)Darolutamide (DB+OL)Placebo (DB)Placebo+Darolutamide (CO)
Urinary retentionRenal and urinary disorders16/95433/95420/5546/170
HaematuriaRenal and urinary disorders11/95425/9547/5540/170
PneumoniaInfections and infestations15/95420/9546/5541/170
Atrial fibrillationCardiac disorders8/9549/9543/5543/170
Cardiac failureCardiac disorders8/95412/9544/5542/170
Urinary tract infectionInfections and infestations7/95412/9540/5541/170
Myocardial infarctionCardiac disorders4/95411/9542/5542/170
HydronephrosisRenal and urinary disorders3/9548/9544/5542/170
Urinary tract obstructionRenal and urinary disorders7/95411/9543/5541/170
AnaemiaBlood and lymphatic system disorders3/9548/9540/5541/170
Most frequent other events
Showing 10 of 57
Most frequent other events
EventDarolutamide (DB)Darolutamide (DB+OL)Placebo (DB)Placebo+Darolutamide (CO)
FatigueGeneral disorders126/954142/95447/5549/170
ArthralgiaMusculoskeletal and connective tissue disorders106/954135/95458/55417/170
Back painMusculoskeletal and connective tissue disorders92/954118/95452/5549/170
AnaemiaBlood and lymphatic system disorders60/95493/95428/5547/170
DiarrhoeaGastrointestinal disorders69/95487/95433/55415/170
HypertensionVascular disorders66/95487/95431/5546/170
ConstipationGastrointestinal disorders65/95484/95436/5548/170
Urinary tract infectionInfections and infestations44/95473/95431/55412/170
Pain in extremityMusculoskeletal and connective tissue disorders60/95471/95419/5545/170
HaematuriaRenal and urinary disorders37/95466/95427/55412/170

Baseline characteristics

Age, Continuous
Age, Continuous(years)Darolutamide (BAY1841788)PlaceboTotal
Mean73.9 ± 7.873.2 ± 8.273.6 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Darolutamide (BAY1841788)PlaceboTotal
Female000
Male9555541509
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Darolutamide (BAY1841788)PlaceboTotal
Asia12271193
Black or African American282452
White7604341194
Missing361955
Other9615
08

Study locations

404 sites
  • Homewood, Alabama 35209, United States
  • Anchorage, Alaska 99503, United States
  • Tucson, Arizona 85704, United States
  • Fountain Valley, California 92708, United States
  • La Jolla, California 92093, United States
  • Laguna Hills, California 92653, United States
  • Los Angeles, California 90048, United States
  • Los Angeles, California 90073-1003, United States
  • San Diego, California 92120, United States
  • Whittier, California 90603, United States
  • Denver, Colorado 80211, United States
  • Denver, Colorado 80220, United States
  • Parker, Colorado 80134, United States
  • Boca Raton, Florida 33486, United States
  • Orlando, Florida 32803, United States
  • Port Saint Lucie, Florida 34952, United States
  • Coeur d'Alene, Idaho 83814, United States
  • Chicago, Illinois 60612, United States
  • Evanston, Illinois 60201-1613, United States
  • Springfield, Illinois 62702, United States
  • Greenwood, Indiana 46143, United States
  • Indianapolis, Indiana 46202, United States
  • Jeffersonville, Indiana 47130, United States
  • West Des Moines, Iowa 50266, United States
  • Wichita, Kansas 67226, United States
  • New Orleans, Louisiana 70121, United States
  • Annapolis, Maryland 21401, United States
  • Baltimore, Maryland 21204, United States
  • Salisbury, Maryland 21801, United States
  • Boston, Massachusetts 02114, United States
  • Grand Rapids, Michigan 49546, United States
  • Royal Oak, Michigan 48073, United States
  • Omaha, Nebraska 68114, United States
  • Omaha, Nebraska 68130, United States
  • Lebanon, New Hampshire 03756-1000, United States
  • Voorhees, New Jersey 08043, United States
  • Bronx, New York 10461, United States
  • Bronx, New York 10469, United States
  • Syracuse, New York 13210, United States
  • Asheboro, North Carolina 27203, United States
  • Charlotte, North Carolina 28277, United States
  • Canton, Ohio 44718, United States
  • Cincinnati, Ohio 45212, United States
  • Cleveland, Ohio 44195, United States
  • Gahanna, Ohio 43230, United States
  • Middleburg Heights, Ohio 44130, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Bala-Cynwyd, Pennsylvania 19004, United States
  • Myrtle Beach, South Carolina 29572, United States
  • Nashville, Tennessee 37209, United States
  • Dallas, Texas 75231, United States
  • Fairfax, Virginia 22031, United States
  • Richmond, Virginia 23235, United States
  • Virginia Beach, Virginia 23462, United States
  • Wheeling, West Virginia 26003, United States
  • Buenos Aires, Ciudad Auton. De Buenos Aires C1120AAT, Argentina
  • Santa Fé, Santa Fe S3000FFV, Argentina
  • San Miguel de Tucumán, Tucuman T4000HXU, Argentina
  • Córdoba, X5000HXL, Argentina
  • Córdoba, X5004FHP, Argentina
  • Córdoba, X5016KEH, Argentina
  • La Rioja, F5300COE, Argentina
  • Randwick, New South Wales 2031, Australia
  • St Leonards, New South Wales 2065, Australia
  • Douglas, Queensland 4814, Australia
  • South Brisbane, Queensland 4101, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Fitzroy, Victoria 3065, Australia
  • Wien, 1020, Austria
  • Wien, 1090, Austria
  • Lesnoy, 223040, Belarus
  • Minsk, 220013, Belarus
  • Bonheiden, 2820, Belgium
  • Kortrijk, 8500, Belgium
  • Libramont, 6800, Belgium
  • Liege, 4000, Belgium
  • Sint-truiden, 3800, Belgium
  • Salvador, Bahia 40050-001, Brazil
  • Fortaleza, Ceará 60430-230, Brazil
  • Goiânia, Goiás 74605-070, Brazil
  • Belo Horizonte, Minas Gerais 30150-320, Brazil
  • Juiz de Fora, Minas Gerais 36010-510, Brazil
  • Uberlandia, Minas Gerais 38408-150, Brazil
  • Curitiba, Parana 81520-060, Brazil
  • Recife, Pernambuco 50070-550, Brazil
  • Passo Fundo, Rio Grande Do Sul 99010-080, Brazil
  • Porto Alegre, Rio Grande Do Sul 90050 170, Brazil
  • Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Itajaí, Santa Catarina 88301-220, Brazil
  • Barretos, Sao Paulo 14784-400, Brazil
  • Jau, Sao Paulo 17210-080, Brazil
  • Ribeirao Preto - SP, Sao Paulo 14048-900, Brazil
  • Sorocaba, Sao Paulo 18035-300, Brazil
  • São Paulo, Sao Paulo 01209-000, Brazil
  • São Paulo, Sao Paulo 01236-030, Brazil
  • São Paulo, Sao Paulo 01246-000, Brazil
  • São Paulo, Sao Paulo 04014-002, Brazil
  • São Paulo, Sao Paulo 04039-004, Brazil
  • Sofia, 1680, Bulgaria
  • Varna, 9000, Bulgaria

Showing the first 100 of 404 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19. PubMed 34797506 ↗
  • Fizazi K, Blue I, Nowak JT. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial. Future Oncol. 2021 May;17(14):1699-1707. doi: 10.2217/fon-2020-1291. Epub 2021 Feb 8. Erratum In: Future Oncol. 2022 Jan;18(2):275. doi: 10.2217/fon-2020-1291c1. PubMed 33554636 ↗
  • Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. PubMed 32905676 ↗
  • Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0. PubMed 31571095 ↗
  • Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. Erratum In: N Engl J Med. 2022 Sep 1;387(9):860. doi: 10.1056/NEJMx220007. PubMed 30763142 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Sep 2018, 47 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 47 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2014
First posted
Jul 25, 2014
StartActual
Sep 12, 2014
Primary completionActual
Sep 3, 2018
CompletionActual
Jun 14, 2021
Results first posted
Oct 29, 2019
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02200614
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 25, 2014
Start date
Sep 12, 2014
Primary completion
Sep 3, 2018
Completion
Jun 14, 2021
Results posted
Oct 29, 2019
Last update
Jun 28, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion